Türkiye'de aşı üretiminde neler oluyor?
Küçük Resim Yok
Tarih
2012
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu yazıda Sağlık Bakanlığı'nın aşı üretimi konusundaki politikası ve ulus ötesi şirketlerin Türkiye'de yürüttükleri çalışmalar tartışılmaktadır. Bu tartışmada iki aşamalı bir yol izlenmiştir. Öncelikle, aşı üretimi sürecinin farklı bileşenlerinin temsilcilerinden bilgi alarak Türkiye'de aşı üretiminde var olan durum tanımlanmıştır. İkinci aşamada ise tanımlanan bu tablo küresel aşı pazarının dinamikleri çerçevesinde sorgulanmıştır. Yapılan değerlendirmeler; Türkiye'deki aşı üretimi çalışmalarının ilaç şirketlerinin dolum ve ambalajlama işlemlerini teknoloji transfer ettikleri fason üreticilere aktarmaları ile sınırlı olduğunu göstermiştir. Bu süreç üretimin son aşamalarını nüfusu sayesinde iyi bir pazar özelliği taşıyan, toplu aşı alımı nedeniyle talepte dalgalanma riski taşımayan Türkiye gibi ülkelere aktaran, böylece özellikle ambalajlama, kalite kontrolü gibi maliyetleri ve riski de bu ülke firmalarına yükleyen ulus ötesi şirketlerin değişen stratejileriyle birebir örtüşmektedir.
The practices carried out in Turkey by transnational companies and the politics of Ministry of Health regarding vaccine production were discussed in this paper. A two-stage method was followed in this discussion. Primarily, current situation in the production of vaccine of Turkey was identified by obtaining information from the representatives of different components of vaccine manufacturing process. In the second stage, however, the chart defined was questioned within the frame of the dynamics of global vaccine market. The evaluations performed showed that vaccination production operations in Turkey are restricted with the subcontractors transferred by pharmaceutical companies to carry out filling and packaging processes through the technology conveyed by the drug firms. This period purely corresponds to the changing strategies of transnational companies which transfer the final stages of the production to countries as Turkey that has a good market feature owing to its population and has no fluctuation risk due to its mass purchase capacity and thus, they particularly impose the costs of packaging, quality control and risks to these country firms, as well.
The practices carried out in Turkey by transnational companies and the politics of Ministry of Health regarding vaccine production were discussed in this paper. A two-stage method was followed in this discussion. Primarily, current situation in the production of vaccine of Turkey was identified by obtaining information from the representatives of different components of vaccine manufacturing process. In the second stage, however, the chart defined was questioned within the frame of the dynamics of global vaccine market. The evaluations performed showed that vaccination production operations in Turkey are restricted with the subcontractors transferred by pharmaceutical companies to carry out filling and packaging processes through the technology conveyed by the drug firms. This period purely corresponds to the changing strategies of transnational companies which transfer the final stages of the production to countries as Turkey that has a good market feature owing to its population and has no fluctuation risk due to its mass purchase capacity and thus, they particularly impose the costs of packaging, quality control and risks to these country firms, as well.
Açıklama
Anahtar Kelimeler
Sağlık Politikaları ve Hizmetleri
Kaynak
Toplum ve Hekim
WoS Q Değeri
Scopus Q Değeri
Cilt
27
Sayı
1
